RecruitingNCT07146503
Real-world use of esketamine nasal spray for hard-to-treat depression
About this title
Read the official source — NCT07146503Observational studyAges 18–74Italy
Understand this study
Who could participate?
Listed age limits: 18 years to 74 years.
- Listed locations
- Genova and 4 more locationsSee all locations and recruitment
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: November 1, 2022
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 100
- Sponsor
- Riccardo Guglielmo
- Sponsor type
- Unknown or unclear
- Study type
- Observational
- Intervention type
- Medication / drug
- Study phase
- Not clearly listed
- Locations
- Italy
- Age range
- From 18 Years to 74 Years
- Official registry ID
- NCT07146503
- Official title
Show the full official title
ESKPSY: Esketamine in Real-World Settings: Clinical Outcomes, Predictors of Response, Life Functioning and Biological Pathways
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Genova · Chieti · Milan
1 more locations
- Pavia
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Riccardo Guglielmo.
Does this study involve medication?
Yes. The study involves medication, including Esketamine (Intranasal Spray).
Who can participate?
Listed age limits: 18 years to 74 years.
Is this study still recruiting?
The registry lists this study as recruiting.
